Research Transparency

Transparency Of Clinical Research

Lack Of Clinical Trial Transparency

Effects Of Failure To Register And Report Clinical Trials

New study shows that 89% of clinical trials run by European universities violate EU regulations

Data released today show that thousands of clinical trials conducted in Europe violate EU rules that require results to be published within 12 months. Failure to publish trial results endangers patients, contributes to exploding drug costs, and slows down the discovery of new treatments and cures.

KEY TAKEAWAYS

• Half of assessed clinical trials, 3,673 in total, are demonstrably in violation of EU rules
• The true number of violations is likely to be far higher, as the researchers excluded 3,392 trials with incomplete registry entries
• 89% of trials sponsored by universities across Europe are missing results
• Around a quarter of all trials have never published results anywhere, meaning that many potentially life-saving medical discoveries are in danger of being lost forever
• National governments across Europe are failing to enforce compliance with regulations designed to strengthen public health and protect patients
• 
  

MOST UNIVERSITIES HAVE A TERRIBLE TRACK RECORD

Universities perform far worse than drug companies.

Only 11% of university-sponsored trials have posted results.

Against this low baseline, the universities of Dundee and Oxford stand out as the best academic performers by far, with results posted for over three quarters of their trials. Over twenty major European medical research universities have not posted any results at all. The worst performer is the Charite in Berlin, which has posted not a single result for at least 63 completed trials.

Current Events

Research Transparency 

Israel's lab developed coronavirus antibody in 'significant breakthrough', says Defense Minister

Jerusalem: Israel has isolated a key coronavirus antibody at its main biological research laboratory, the Israeli defence minister said on Monday, calling the step a “significant breakthrough” toward a possible treatment for the COVID-19 pandemic.The “monoclonal neutralising antibody” developed at the Israel Institute for Biological Research (IIBR) “can neutralise it (the disease-causing coronavirus) inside carriers’ bodies,” Defence Minister Naftali Bennett said in a statement.

                                                         Snapshot

                                    Coronavirus Research Transparency